Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Lantheus (LNTH)

Lantheus completes $350 million Life Molecular Imaging acquisition, names new R&D head

Neutral Impact 4 of 5 m&a Written later

Lantheus said on July 21, 2025 it completed its acquisition of Life Molecular Imaging Limited from Life Healthcare Group, paying an upfront cash amount of $350 million after purchase price adjustments. The deal adds Neuraceq, an F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer's disease, along with commercial infrastructure and R&D capabilities. The filing does not provide financial results or guidance for the acquired business.

Key points

  • Upfront cash payment of $350 million to the seller, after applicable purchase price adjustments
  • Transaction completed July 21, 2025; agreement first announced January 12, 2025
  • Dr. Ludger Dinkelborg, formerly CEO of Life Molecular Imaging, becomes Head of Research and Development effective August 1, 2025, reporting to CEO Brian Markison

The filing

CompanyLantheus (LNTH)
Form8-K, current report
Filed with the SECJul 22, 2025, 7:31 AM ET
Accession number0001193125-25-162233

Items reported: 2.01 Acquisition or Disposition Completed7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 22, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.